All In Biotech

Drug Trial Radar · NCT06111014

Continuation Study for Latozinemab

A Continuation Study of Latozinemab in Participants With Neurodegenerative Disease

Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

17

Actual

Start

Dec 8, 2023

Primary completion

Sep 1, 2025

Study completion Jan 7, 2026

Sponsor

Lead sponsor
Alector Inc.Industry
Sponsor type
Industry
First posted
Nov 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

Conditions

  • Neurodegenerative Diseases

Interventions

  • LatozinemabDrug

    All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants receiving latozinemabTime frame: Through study completion, up to 190 weeks
  2. Duration of treatment with latozinemabTime frame: Through study completion, up to 190 weeks

Locations

18 sites in 10 countries. Site status is shown where the registry gives one.

  • Dignity Health - Arizona

    Phoenix, Arizona

  • Mayo Comprehensive Cancer Center - PPDS

    Rochester, Minnesota

  • Irving Institute for Clinical and Translational Research

    New York, New York

  • University of Cincinnati Gardner Neuroscience Institute

    Cincinnati, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • UZ Leuven

    Leuven, Belgium

  • Parkwood Institute

    London, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Groupe Hospitalier Pitié Salpétrière

    Paris, France

  • Universitätsklinikum Ulm - Leimgrubenweg 12-14

    Ulm, Germany

  • IRCCS - Centro S. Giovanni di Dio Fatebenefratelli

    Brescia, Italy

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico -Via Fracesco Sforza 35

    Milan, Italy

  • Azienda Ospedaliero Universitaria Di Modena Policlinico

    Modena, Italy

  • Erasmus MC-Dr. Molewaterplein 40

    Rotterdam, Netherlands

  • Centro Hospitalar E Universitario de Coimbra EPE

    Coimbra, Portugal

  • Centro Hospitalar Universitário Lisboa Norte, EPE - Hospital de Santa Maria

    Lisbon, Portugal

  • Karolinska Universitetssjukhuset Huddinge

    Huddinge, Sweden

  • University College London

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.